AAIPharma, Inc. Appoints Senior Director of Biopharmaceutical Development
Published: Dec 07, 2012
WILMINGTON, N.C., Dec. 7, 2012 /PRNewswire/ -- AAIPharma Services Corp. ("AAIPharma"), a leading provider of pharmaceutical product development services, announced today that it has appointed Timothy Rhines, Ph.D., RAC as the company's senior director of biopharmaceutical development for its Wilmington, N.C. laboratory.
"Tim's focus on customer service and high-quality deliverables makes him a perfect fit for our organization" said Paul Maffuid, executive vice president of AAIPharma's laboratory operations. "His demonstrated leadership within the CMC analytical sector complements our service offerings and will capitalize on the recent biopharmaceutical advancements made within our Wilmington Technology Center."
Dr. Rhines joins AAIPharma with more than 22 years of experience in laboratory management, most recently with Covance Laboratories as the director of chemistry, manufacturing, and controls (CMC) pharmaceutical development services for North America.
"AAIPharma offers exceptional services and a broad expertise in the field of biopharmaceutical services. Our vision is to continue the growth within AAIPharma's biopharmaceutical development team" Dr. Rhines said. "AAIPharma's staff of experienced and talented scientists, coupled with recently added state of the art instrumentation within its Technology Center, will continue to establish AAIPharma as an industry leader for biopharmaceutical development and characterization."
Dr. Rhines earned his undergraduate degree in chemistry from the University of Northern Iowa, and a doctorate in analytical chemistry from the University of Iowa. In addition, Dr. Rhines is a member of the Regulatory Affairs Professional Society, the American Association of Pharmaceutical Sciences and is a past participant in the Midwest United States Pharmacopeia Discussion Group.
About AAIPharma Services Corp.
AAIPharma Services Corp. is a leading provider of contract services that support all phases of drug development. The company's wide array of capabilities includes analytical chemistry, formulation development, material testing services, microbiology, clinical and commercial contract manufacturing, pharmaceutical packaging and stability services. Serving more than 600 clients around the globe and headquartered in Wilmington, N.C., AAIPharma is a portfolio company of Water Street Healthcare Partners, a strategic private equity firm focused exclusively on health care.
For more information on the company, visit www.aaipharma.com.
SOURCE AAIPharma Services Corp.